This website is intended for healthcare professionals only
User log in

Trial log in

Targets for glycaemic control in type 2 diabetes

This promotional module has been initiated, funded and reviewed solely by Boehringer Ingelheim. The content of this industry-supported learning activity has been  generated by Practice Nurse.

Links to prescribing information can be found at the foot of this page. 



Increasingly, day-to-day management of people with type 2 diabetes falls to general practice nurses (GPNs).1 It is therefore important that they are familiar with the latest guidelines, and understand how to apply the recommendations to their individual patients. This includes recognising how to determine appropriate targets (for example, for blood glucose control) in each individual case.

This module will help improve awareness of the role of adequate blood glucose control in the prevention of the complications of diabetes


On completion of this module, you will be aware of:

  • Current targets as recommended in the recent national and international guidelines
  • The importance of agreeing targets with individual patients
  • When to intensify drug treatment to achieve targets
  • When to consider relaxing the target (on a case-by-case basis)
  • The importance of good blood glucose control for the prevention of complications.

This module is one of a series of five. Others in the series are:

This resource is provided at an intermediate level. Read the article and answer the self-assessment questions, and reflect on what you have learned.

Complete the resource to obtain a certificate to include in your revalidation portfolio. You should record the time spent on this resource in your CPD log.


1. Royal College of Nursing. Education, prevention and the role of the nurse. (Updated November 2020). [Accessed June 2022]

Job Code: PC-GB-105008

Date of preparation: June 2022

You can sign up here to receive and manage your electronic communications from Boehringer Ingelheim and its agents acting on its behalf, about BI's products, services and events.

Click here for Trajenta (linagliptin) Prescribing Information: Great Britain | Northern Ireland

Click here for Jardiance (empagliflozin) Prescribing Information: Great Britain | Northern Ireland

Adverse events should be reported. Reporting forms and information can be found at Adverse events should also be reported to Boehringer Ingelheim Drug Safety on 0800 328 1627 (freephone).